After breaking the main cost line, BIO has doubled! Will ORDI be next?
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.
On Tuesday, ASML (ASML.US) became the focus of the market as Bank of America praised the company's additional chip manufacturing equipment supply agreements with TSMC (TSM.US), Intel (INTC.US), and Samsung.
Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating
Amgen's stock posted its biggest single-day decline since 2016 on Tuesday, after Novartis announced that a heart disease therapy jointly developed with Ionis Pharmaceuticals suffered a setback in late-stage clinical trials. Meanwhile, BMO downgraded the pharmaceutical giant's rating from "Outperform" to "Market Perform," citing the failure of its candidate drug pelacarsen to meet expectations in its phase III clinical trial.
NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions
Rothe Development, a contractor that provides engineering and mission operations services to NASA and other federal agencies, filed on Tuesday with the SEC to raise up to $50 million through an initial public offering (IPO).
Eldorado Gold Produces First Copper-Gold Concentrate at Greek Mine
Crypto prices
More
